SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec's acute care portfolio in the UK and Ireland

(sphingotec GmbH) The collaboration in particular focuses on the UK market introduction of SphingoTec's point-of-care tests for novel and proprietary biomarkers in critical care targeting diagnostically underserved conditions such as sepsis, acute heart failure, acute kidney injury, and recently severe COVID-19.
Source: EurekAlert! - Biology - Category: Biology Source Type: news